Experimental CAR-T therapy targets tough solid tumors in small pilot trial
NCT ID NCT06556108
First seen Jan 22, 2026 · Last updated Apr 30, 2026 · Updated 12 times
Summary
This study tested a new treatment called Anti-ALPP CAR-T cells in 5 people with advanced solid tumors that had not responded to standard therapies. The treatment uses a patient's own immune cells, modified to attack a protein (ALPP) found on many cancer cells. The main goals were to check safety and see if tumors shrank.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Hematology, Xinqiao Hospital
Chongqing, Chongqing Municipality, 400037, China
Conditions
Explore the condition pages connected to this study.